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Abstract
Background: To investigate the predictive significance of KRAS, BRAF, PIK3CA mutational status, AREG- EREG mRNA
expression, PTEN protein expression and skin rash in metastatic colorectal cancer (mCRC) patients treated with cetuximab
containing salvage chemotherapy.
Methods: Primary tumors from 112 mCRC patients were analyzed. The worst skin toxicity during treatment was recorded.
Results: KRAS, BRAF and PIK3CA mutations were present in 37 (33%), 8 (7.2%) and 11 (9.8%) cases, respectively, PTEN was
lost in 21 (19.8%) cases, AREG and EREG were overexpressed in 48 (45%) and 51 (49%) cases. In the whole study population,
time to tumor progression (TTP) and overall survival (OS) was significantly lower in patients with KRAS (p=0.001 and
p=0.026, respectively) or BRAF (p=0.001 and p,0.0001, respectively) mutant tumors, downregulation of AREG (p=0.018
and p=0.013, respectively) or EREG (p=0.002 and p=0.004, respectively) and grade 0-1 skin rash (p,0.0001 and p,0.0001,
respectively). In KRAS wt patients TTP and OS was significantly lower in patients with BRAF (p=0.0001 and p,0.0001,
respectively) mutant tumors, downregulation of AREG (p=0.021 and p=0.004, respectively) or EREG (p=0.0001 and
p,0.0001, respectively) and grade 0-1 skin rash (p,0.0001 and p,0.0001, respectively). TTP was significantly lower in
patients with PIK3CA mutations (p=0.01) or lost PTEN (p=0.002). Multivariate analysis revealed KRAS (Hazard Ratio [HR] 4.3,
p,0.0001), BRAF mutation (HR: 5.1, p,0.0001), EREG low expression (HR: 1.6, p=0.021) and absence of severe/moderate
skin rash (HR: 4.0, p,0.0001) as independent prognostic factors for decreased TTP. Similarly, KRAS (HR 2.9, p=0.01), BRAF
mutation (HR: 3.0, p=0.001), EREG low expression (HR: 1.7, p=0.021), absecence of severe/moderate skin rash (HR: 3.7,
p,0.0001) and the presence of undifferantited tumours (HR: 2.2, p=0.001) were revealed as independent prognostic factors
for decreased OS.
Conclusions: These results underscore that KRAS-BRAF mutations and EREG expression can be used as biomarkers to further
select patients undergoing anti-EGFR treatment.
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Introduction
Despite the progress made in the management of metastatic colorectal
cancer (mCRC) over the last few years, the disease remains a major
public health problem in the western world with an estimated 146,970
new CRC cases and 49,920 deaths for 2009 in the United States [1].
Two monoclonal antibodies targeting EGFR (anti-EGFR moAbs),
both by binding to the extracellular domain, and thus, leading to
inhibition of its downstream signaling, the chimeric IgG1 moAb
cetuximab and the fully humanizedI g G 2m o A bp a n i t u m u m a b ,h a v e
entered clinical practice in the mCRC setting and have proven to
provide a modest clinical benefit in pretreated patients, either used alone
or in combination with chemotherapy [2–5]. Nevertheless, from the
beginning became clear that not all patients derive a benefit from the
incorporation of these agents into the treatment combinations; indeed,
non-randomized retrospective studies [6–11] as well as retrospective
analysis of prospective randomized trials [12–16] demonstrated that the
presence of KRAS mutations were predictive of resistance to anti-EGFR
moAbs therapy and were associated with a worse prognosis and a
shorter survival. Based on this knowledge, a primary tumor’s KRAS
mutational status is now mandatory for the treatment of metastatic
disease with an anti-EGFR moAb (European Medicine Agency –
EMEA-H-C-741 and H-C-558 and U.S. Food and Drug Administra-
tion - FDA Application No. (BLA) 125084 and No. (BLA) 125147).
However, not all patients with KRAS WT tumours benefit from
anti-EGFR moAbs treatment, meaning that additional genetic
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sporadic mCRC retrospective studies [20–22], the BRAF V600E
mutation has been shown to identify a subgroup (,10%) of patients
that not only present resistance to anti-EGFR MoAbs therapy, but,
is also characterized by particularly unfavorable prognosis regard-
less of treatment administration [20–22]. Furthermore, although
not entirely clear yet, PIK3CA-mutant tumors seem to derive no or
little benefit from anti-EGFR MoAbs treatment [20,23–26].
Besides the KRAS-BRAF-PIK3CA mutational status, EGFR
epiregulin (EREG) and ampiregulin (AREG) ligands’ expression in
primary CRC tumours has been shown to significantly predict
clinical outcome in KRAS WT mCRC patients treated with
cetuximab, indicating ligand-driven autocrine oncogenic EGFR
signaling [27,28]. In addition, PTEN (phosphatase and tensin
homolog) protein expression, and specifically its loss, seems to be
associated in a number of studies with resistance to treatment with
anti-EGFR MoAbs treatment [21,29–31]. Furthermore, from a
clinical point of view, the only parameter which has been constantly
associated with a high probability of response, prolonged progres-
sion-free survival (PFS) and median Overall Survival (mOS) to anti-
EGFR moAbs treatment is the development of skin rash [2,5,32].
Clinical parameters seem to be inadequate for patient selection,
but, biomarkers’ analyses have already been incorporated in the
treatment of CRC patients. The aim of the present study was to
simultaneously ascertain and investigate the clinical relevance of
all known biomarkers, KRAS exon 2, BRAF V600E, PIK3CA exon
9 and 20 mutational status in conjunction with AREG, EREG
mRNA expression, PTEN immunohistochemical protein expres-
sion, as well as, skin rash development, in mCRC patients treated
with cetuximab containing salvage combination chemotherapy.
Materials and Methods
Patient population and study design
One hundred and twelve consecutive patients, with histologi-
cally confirmed mCRC and available tumor material for
molecular analysis, who were treated with cetuximab containing
salvage chemotherapy at the Department of Medical Oncology,
University Hospital of Heraklion (Crete, Greece) between 1/2005
- 12/2008, were enrolled. The study was approved by the Ethics
and Scientific Committees of the University General Hospital of
Heraklion and all patients gave their written informed consent for
the use of the tissue material for translational research.
Patients’ evaluation was performed at baseline and every four
cycles of chemotherapy. Disease status was coded, without the
knowledge of the laboratory analysis.
Tissue selection, DNA and RNA extraction
Formalin-fixed, paraffin-embedded (FFPE) tumor sections were
reviewed by a pathologist (MT) to confirm the diagnosis and define
tumor-enriched areas for dissection. Ten serial sections of 5 mm
thickness were stained with nuclear fast red (Sigma-Aldrich, St
Louis, MO, USA) and scrape dissection under a binocular
microscope was performed for samples with $80% tumor cells;
for samples with ,80% malignant cells, microdissection with the
piezoelectric Eppendorf microdissector (Eppendorf, Hamburg,
Germany) was performed. DNA extraction was performed with
the use of the EpicentreH Biotechnologies MasterPure
TM Complete
DNA and RNA Purification Kit according to the manufacturer’s
instructions(Epicentre,Madison,WI,USA)aftertheisolatedcancer
cells were lysed in buffer containing Proteinase K at 60uC for 72 h.
For RNA extraction, cancer cells were re-suspended in 400 ml RNA
lysis buffer supplemented with 300 mg proteinase K (QIAGEN,
Valencia, CA, USA) and incubated at 60uC for 16 hours until the
tissue was completely solubilized. RNA was purified by Trizol LS
(Invitrogen, Carlsbad,CA,USA) and, subsequently, treated with
DNase (DNA- free, Ambion, Austin, TX, U.S.A.) in order to avoid
genomic DNA contamination and stored at -80uC until used.
KRAS and PIK3CA mutational analysis
KRAS and PIK3CA mutational analysis was performed by
Sanger sequencing after PCR amplification of KRAS exon 2 and
PIK3CA exons 9 and 20. PCR conditions with primers sets which
have been previously reported [22].
BRAF mutational analysis
The V600E BRAF mutation was detected by real-time PCR using
the allelic discrimination method as previously described [33,34]. In
brief, the DNA extracted from tumoral cells was amplified with the use
of a set of primers and two hydrolysis probes in the ABI PRISM 7900T
Sequence Detection System (AB; Applied Biosystems, Forest City; CA;
USA). The two hydrolysis probes were labeled at 5 with VIC and FAM
fluorophores reporters for the wt and the mutant allele, respectively.
The SDS 2.3 software was used for the analysis of the results.
AREG and EREG mRNA expression
The SuperScript III Reverse Transcriptase (Invitrogen, Carls-
bad, CA, U.S.A.) was used to prepare cDNA from 50 ng of total
RNA for each gene analyzed as previously described [35]. Relative
cDNA quantification for AREG, EREG and both b-actin and PGK
as internal reference genes was done using the ABI Prism 7900HT
Sequence Detection System (AB), as described previously [35].
The primers and probe sets were designed using Primer Express
2.0 Software (AB), according to the Ref Seq NM_001657.2 for
AREG and NM 001432.2 for EREG (http://www.ncbi.nlm.nih.
gov/LocusLink). The sequence of the primers and 59 labeled
fluorescent reporter dye (6FAM) probes for all reference and target
genes are shown in Table 1.
Relative gene expression quantification was performed accord-
ing to the comparative Ct method using b-actin and PGK as
endogenous controls and commercial RNA controls (Stratagene,
La Jolla, CA, USA) as calibrators. Final results were determined as
follows: 2
-(DCt sample-DCt calibrator), where DCT values of the
Table 1. Sequence of the primers and probes of all references and target genes.
Gene Forward Primer 59-labeled (FAM) probe Reverse Primer
b-actin 59-GGC ACC CAG CAC AAT GAA G-39 59 TCA AGA TCA TTG CTC CTC CTG AGC GC--3 ’59-GCC GAT CCA CAC GGA GTA CT-39
PGK 59- GGCTGGATGGGCTTGGA –39 5-TGTGGTCCTGAAAGCAGCAAGAAGTATGC -39 59-TCTGCTTAGCCCGAGTGACA-3
AREG 59- GTGGTGCTGTCGCTCTTGATAC -39 5- CGGCTCAGGCCATTATGCTGCTG-39 59-AGAGTAGGTGTCATTGAGGTCCAAT-39
EREG 59- TGCATCTATCTGGTGGACATGAG -39 5-AAAACTACTGCAGGTGTGAAGTGGT-39 59-AGTGTTCACATCGGACACCAGTA –39
doi:10.1371/journal.pone.0015980.t001
Biomarkers to Anti-EGFR moABS in mCRC
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value of the target gene from the mean value of both reference
genes. In all experiments, only triplicates with a standard deviation
(SD) of the Ct value ,0.25 were accepted. In addition, genomic
DNA contamination of each sample has been excluded by non-
reverse transcription of RNA [35].
PTEN protein expression
Three- to 4- mm tumor tissue sections of paraffin-embedded
specimens from each patient were selected for PTEN IHC staining
using the 17.A mouse monoclonal antibody (1:25 dilution,
Neomarkers; ThermoFisher Scientific Inc, Fremont, CA), as
previously described [28,36]. After deparaffinization and hydration
of sections, antigens were unmasked by heat in EDTA buffer.
Immunostaining was performed using the UltraVision LP Large
Volume Detection System AP Polymer (Thermo Scientific, Wal-
tham, MA, USA). Negative control slides were prepared by omitting
the primary antibody. Prostate cancers and endothelial cells were
used as external and internal positive controls, respectively.
PTEN staining was mainly cytoplasmatic. As previously
described [28], intensity was scored according to a four-tier system:
0, no staining; 1, weak; 2, moderate; and 3, strong. One, two or
three additional points were attributed if the percentage of positive
was ,25%, 25–50% or .50%, respectively. The specimens with a
cumulative score of $4 were characterized as positive [28].
Study Design and Statistical analysis
The present study was a retrospective analysis aiming to explore
the predictive value of extensive biomarkers analysis in the
outcome of patients with mCRC treated with cetuximab plus
chemotherapy as salvage treatment. All available biopsies of the
primary tumor with more than 100 cells per section were included
in the analysis. RT-qPCR analysis yielded values that were
expressed as ratios between two absolute measurements (gene of
interest: mean of internal reference genes). CART analysis has
been used for the estimation of the cut-off points of AREG and
EREG mRNA expression, in order to classify cases into groups of a
dependent (TTP and mOS) variable. Samples with mRNA
expression above or equal to the cut-off point were considered
as samples with high expression, while those with value below the
median as samples with low expression. Associations between
KRAS, BRAF, PIK3CA mutation status, AREG and EREG mRNA
expression and PTEN IHC expression with baseline characteris-
tics were assessed using the Fisher’s exact test for categorical
variables or logistic regression for continuous variables. Spear-
man’s exact test was used to evaluate the correlation between
AREG and EREG mRNA expression. Time to tumour progression
(TTP) and overall survival (OS) were measured from the date of
the cetuximab containing treatment line initiation to the first
radiographic documentation of disease progression or death,
respectively. Kaplan–Meier curves were used to describe the
proportion of patients who remained free of events over the follow-
up period. Associations between prognostic factors and TTP or
OS were examined using Cox proportional hazards regression
models. All reported p-values are two-sided and not adjusted for
multiple testing.
Results
Patient demographics
The mutational status for KRAS exon 2, BRAF exon 15, and
PIK3CA exons 9 and 20 was determined in all 112 consecutive
patients with mCRC whereas. AREG and EREG mRNA
expression was determined in 106 and 105 patients for whom
tumour material was available respectively, while PTEN expres-
sion was evaluated in 106 patients. All patients were treated with
cetuximab in combination with chemotherapy (73% in combina-
tion with Irinotecan, 27% with Oxaliplatin) as salvage treatment
(Table 2). Sixty-six (59%) patients had received the treatment in
the 2
nd line setting and the remaining 46 (41%) as 3
rd line
treatment. There was no patient who received the anti-EGFR
moAbs in the 1
st line setting. Disease characteristics were typical
for mCRC in the western world; the patients’ median age was 66
years and 60% of them were male (Table 2). The median PFS
from 1
st line treatment was 8.9 months (95% CI 8.1-9.9) and the
median time from relapse to previous treatment line until the
cetuximab administration was 1.1 months (95% CI 0.7–1.8).
Mutational status and expression values results
KRAS mutations were detected in 37 (33%), BRAF mutations in
eight (7.2%) and PIK3CA mutations in 11 (9.8%, 8 in exon 9 and 3
in exon 20) primary tumours, respectively. KRAS and BRAF
mutations were mutually exclusive, whereas, three tumours carried
both KRAS and PIK3CA mutations. AREG and EREG were
overexpressed in 48 (45%) and 51 (49%) patients, respectively,
whereas, PTEN was scored as negative (i.e. loss of function) in 21
(19.8%) patients (Figures 1A and 1B). When PIK3CA mutations
and PTEN expression were analyzed together, activation of the
pathway (defined as loss of PTEN or PIKECA mutation) was
detected in 25 (23.5%) patients. A trend for decreased incidence of
Table 2. Patients9 and tumors9 characteristics.
Feature N %
112
Median Age (Range) 66(23–83)
#70 years 76 78
.70 years 36 32
Gender
Male 68 60
Female 44 40
Stage at diagnosis
I-III 61 54
IV 51 46
Tumor Location
Colon 83 74
Rectum 29 26
Tumor differentiation
Well moderate 66 59
Undifferentiated 46 41
Mucinous Features
Yes 18 16
No 94 84
Cetuximab administration line
2nd 66 59
3rd 46 41
Chemotherapy administered with
Cetuximab
Irinotecan-based 82 73
Oxaliplatin-based 30 27
doi:10.1371/journal.pone.0015980.t002
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of the 83 (37%) tumours located at the colon and six of the 29
(20%) tumours located at the rectum harbored a KRAS mutation.
There was no correlation between the presence of KRAS mutations
with the patients’ gender, age (.70 years old versus #70 years
old), stage at diagnosis, histological grade, mucinous status, PTEN
loss and AREG-EREG expression (all p-values .0.05). Also, a
statistically significant correlation was observed between the
presence of BRAF mutations and the histological grade (well/
moderate versus undifferentiated) (p=0.049) and EREG mRNA
downregulation (p=0.013). There was no correlation between the
presence of BRAF and PIK3CA mutations with the patients’
gender, age (.70 years old versus #70 years old), stage at
diagnosis, tumour location, mucinous status, PTEN loss and AREG
expression (in both cases all p-values .0.05).
Impact of mutational status and expression values on the
outcome of salvage cetuximab therapy
Results in the whole patients’ population (Table 3). Tables 3
and 4 summarize the impact of genetic alterations on the outcome of
cetuximab-containing salvage treatment. The median TTP of the whole
group of patients was 4.9 months (95% CI 4.1–5.7) and the
corresponding median overall survival (OS) 14.5 months (95% CI
10.0–18.9). TTP and OS were significantly lower among patients whose
tumours carried KRAS mutations (3.1 vs. 6.4 months, p=0.001 and 10.6
vs. 16.3 months, p=0.026, respectively) (Figure 2A and 2B).
Similarly, TTP and OS were significantly lower among patients
whose tumours carried BRAF mutations (2.1 vs. 5.2 months, p=0.001
and 4.3 vs. 15.1 months, p,0.0001, respectively) (Figure 3 and 4).
There was no significant correlation in terms of TTP according to
PIK3CA mutational status or PTEN expression in all treated patients (4.9
vs. 5. 7 months, p=0.427 and 5.2 vs. 6.03. months, p=0.102,
respectively) (Figure 4A and 4B); similarly, there was no difference in
terms of median OS between patients with PIK3CA mutant (13.6
months) and wt (15.0 months) primary tumours (p=0.44;Figure 5A),
as well as between patients with lost (14.3 months) or normal (15.1
months) PTEN function (p=0.82; Figure 5B). Nevertheless, when
PIK3CA mutational status and PTEN expression were taken into
consideration together, activation of the pathway through PIK3CA
mutations and/or PTEN loss was correlated with a trend for decreased
TTP in all patients (3.8 vs. 5.0 months, p=0.051)(Figure 4E),w h i l en o
difference was observed in the median OS (13.9 vs. 14.5 months,
p=0.878)(Figure 5E).
A highly significant correlation between AREG and EREG
mRNA expression was observed (Spearman r
2=0.736, p,0.001).
In the whole group of patients, AREG mRNA overexpression was
significantly correlated with increased TTP and OS (5.0 vs. 3.8
months, p=0.018 and 20.2 vs. 10.7 months, p=0.013, respec-
tively]) (Figures 6A and 6B). Furthermore, EREG mRNA
overexpression was also correlated significantly with increased
TTP and OS (6.1 vs. 3.6 months, p=0.002 and 17.6 vs. 10.7
months, p=0.004, respectively) (Figures 7A and 7B).
Table 3 and Figures 8A and 8B demonstrate the differences
in TTP and OS according to KRAS–BRAF mutational status and
AREG expression. It is shown that the KRAS-BRAF WT and AREG
overexpression profile was correlated significantly with increased
TTP and OS compared with any other combination. Similarly,
Figures 8C and 8D and Table 3 illustrate the differences in
TTP and OS according to KRAS–BRAF mutational status and
EREG expression; again, the KRAS-BRAF WT and EREG
overexpression profile was correlated significantly with increased
TTP and OS compared with any other combination.
Finally, we correlated the impact of cetuximab induced skin
rash with treatment outcome. Patients with severe or moderate
(grade 2–3) skin rash presented significantly higher TTP (7.5
months) in comparison with those with mild (grade 1) (4.5 months;
p,0.0001) and no skin rash (2.3 months, p,0.0001), as well as
increased OS (24.1 vs. 13.2 months, p,0.0001, and vs. 4.9
months, p,0.0001) (Table 3 and Figures 9A and 9B).
ResultsintheKRASWTpatients’population(Table4). When
only KRAS WT cases were analyzed patientsw h o s et u m o u r sc a r r i e dt h e
BRAF mutation had even more significantly lower TTP and OS (TTP:
2 . 1v s .6 . 4m o n t h s ,p,0.0001; OS: 4.3 vs. 16.3 months, p ,0.0001)
(Figure 3C and 3D) compared with the results in the whole
population. In addition, when only the KRAS WT cases were considered,
decreased TTP was significantly associated with the presence of PIK3CA
mutation (4.3 vs. 6.4 months, p=0.01) (Figure 4C) and PTEN
downregulation (3.7 vs. 5.0 months, p=0.002) (Figure 4D).
Nevertheless, in this particular group of patients with KRAS WT
tumors, no significant correlation was found in the median OS between
patients with or without PIK3CA mutations (13.5 vs. 16.3 months,
respectively; p=0.345) or those with downregulated or functional PTEN
(15.3 vs. 14.5 months, respectively; p=0.862) (Figures 5C and 5D).
But, in KRAS WT patients when PIK3CA mutational status and PTEN
expression were taken into consideration together, a significantly
decreased TTP was observed with the activation of the pathway
through PIK3CA mutations and/or PTEN loss, compared with its
inactivated presence with wt PIK3CA and/or functional PTEN (3.8 vs.
6.4 months, p=0.001)(Figure 4F); conversely, such a correlation could
not be revealed in terms of median OS (13.9 vs. 16.2 months; p=0.987)
(Figure 5F).
Figure 1. Assessment of PTEN expression by immunohisto-
chemistry. Panel A: Sample of a moderate differentiated adenocarci-
noma of the colon scored as PTEN positive (x100) Panel A: Sample of a
moderate differentiated adenocarcinoma of the colon scored as PTEN
negative (x100).
doi:10.1371/journal.pone.0015980.g001
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significantly correlated with increased TTP and OS (5.8 vs. 4.3
months, p=0.021 and 23.2 vs. 10.7 months, p=0.004, respec-
tively) (Figures 6C and 6D), as well as, EREG mRNA
overexpression (7.0 vs. 3.8 months, p=0.0001 and 20.2 vs. 10.5
months, p,0.0001, respectively) (Figures 7C and 7D).
Univariate and Multivariate analysis
As far as TTP was concerned, the univariate analysis (Table 3
and 4) demonstrated significant associations with: i) KRAS
mutations (p=0.001); ii) BRAF mutations (p=0.001); iii) AREG
mRNA expression (p=0.018); iv) EREG mRNA expression
(p=0.002) and v) the development of moderate severe skin rash
(p,0.0001). In addition, TTP in KRAS wt patients was significantly
correlated with PIK3CA mutation (p=0.01), PTEN expression
(p=0.002) and the PIK3CA-PTEN axis activation (p=0.001). As far
as OS was concerned the univariate analysis (Table 3 and 4)
demonstrated significant associations with: i) KRAS mutations
(p=0.026); ii) BRAF mutations (p,0.0001); iii) AREG mRNA
expression (p=0.013); iv) EREG mRNA expression (p=0.004) and
Table 3. TTP and OS to the $2
nd line cetuximab-containing treatment according to KRAS, BRAF, PIK3CA mutations status, PTEN
protein expression, AREG and EREG mRNA expression and grade of skin rash in the whole patient9 population.
Time to Tumor Progression (months) Overall survival (months)
All patients n=112 4.9 months (95% CI 4.1–5.7) 14.5 months (95% CI 10.0–18.9).
Feature
Patients9 population
(No of patients)
Median (months)
(95% CI*)
HR
#
(95% CI) p value
Median (months)
(95% CI)
HR
(95% CI) p value
KRAS status n=112 Mutant (n=37) 3.1 (2.0–4.2) 3.3 (2.4–5.1) 0.001 10.6 (5. 7–15.5) 2.2 (1.7–2.8) 0.026
WT
‘ (n=75) 6.4 (5.4–7.4) 16.3(12.7–19.6)
BRAF status n=112 Mutant (n=8) 2.1 (0.8–3.3) 4.9 (2.2–10.9) 0.001 4.3 (0.3–10.3) 3.6 (1.7–7.5) ,0.0001
WT
‘ (n=104) 5.2 (4.3–6.1) 15.1 (12.2–17.9)
PIK3CA status n=112 Mutant (n=11) 4.9 (2.9–6.9) 1.9 (0.9–4.1) 0.427 13.6 (4.9–19.2) 1.3 (0.7–2.9) 0.44
WT
‘ (n=101) 5.7 (4.8–6.8) 15.0 (13.2–22.2)
PTEN expression n=106 Loss (n=21) 5.2 (4.1–6.3) 1.7 (0.97–2.8) 0.102 14.3 (2.6–18.8) 1.1 (0.6–1.8) 0.82
Preserved (n=85) 6.0 (4.9–7.2) 15.1 (9.8–24.3)
PIK3CA-PTEN axis n=106 Activated (n=25) 3.8 (2.7–4.9) 1.6 (1.0–2.6) 0.051 13.9 (7.8–20.0) 1.1 (0.7–1.7) 0.878
Normal (n=81) 5.0 (3.9–6.1) 14.5 (9.6–19.4)
AREG expression n=106 Downregulated (n=58) 3.8 (2.7–4.9) 1.7 (1.1–3.2) 0.018 10.7 (9.5–11.9) 1.7 (1.1–2.6) 0.013
Overexpressed (n=48) 5.0 (3.9–6.1) 20.2 (12.8–27.6)
EREG expression n=105 Downregulated (n=54) 6.1 (3.9–8.3) 2.1 (1.3–3.1) 0.002 10.7 (9.5–11.9) 1.8 (1.2–2.8) 0.004
Overexpressed (n=51) 3.6 (2.00–5.3) 17.6 (12.6–22.7)
Skin rash n=112 None (n=24) 2.3 (1.9–2.7) 5.1 (2.9–9.1)
$ ,0.0001
$ 4.9 (2.8–6. 9) 5.3 (3.0–9.4)
$ ,0.0001
$
Grade 1 (n=40) 4.5 (3.3–5.7) 2.5 (1.5-4.0)
@ ,0.0001
@ 13.2 (8.9–17.5) 2.2 (1.4-3.7)
@ ,0.0001
@
Grade 2–3 (n=48) 7.5 (6.0–9.0) 24.1 (21.4–26.7)
KRAS -BRAF
-AREG genotype
KRAS or BRAF mutant AREG
downregulated
(n=25) 2.3 (1.8–2.9) 7.0(3.8–12.9)
& ,0.0001
& 9.9 (6.1–13.7) 3.1(2.1–3.6)
& 0.001
&
KRAS or BRAF mutant AREG
overexpressed
(n=14) 3.1 (2.1–4.1) 5.1 (2.64–10.0)
‘ ,0.0001
‘ 10.2 (3.7–16.6) 2.2 (1.3–3.8)
‘ 0.017
‘
KRAS or BRAF WT AREG
downregulated
(n=33) 4.6 (3.8–5.4) 2.5 (1.5–4.2)
£ ,0.0001
£ 10.2 (8.8–11.6) 2.0 (1.1–3.8)
£ 0.019
£
KRAS or BRAF WT AREG
overexpressed
(n=34) 9.9 (7.6–12.2) 23.3 (21.3–25.2)
KRAS -BRAF
-EREG genotype
KRAS or BRAF mutant EREG
downregulated
(n=19) 2.2 (1.9–2.5) 16.8(11.8–31.4)
& ,0.0001
& 9.2 (3.2–15.1) 3.5(2.5–4.4)
& ,0.0001
&
KRAS or BRAF mutant EREG
overexpressed
(n=17) 3.5 (2.4–4.6) 6.8 (3.4–13.8)
‘ ,0.0001
‘ 10.1 (5.6–14.7) 2.2 (1.2–3.9)
‘ 0.013
‘
KRAS or BRAF WT EREG
downregulated
(n=35) 5.0 (4.3–5.8) 2.6 (1.5–4.3)
£ ,0.0001
£ 10.2 (9.1–11.3) 2.1 (1.1–3.8)
£ 0.015
£
KRAS or BRAF WT EREG
overexpressed
(n=34) 8.2 (5.3–11.1) 23.2 (17.8–28.7)
*CI: Confidence Interval,
#HR: Hazard Ration,
‘WT: Wild Type,
$Skin rash grade 2–3 vs. none,
@Skin rash grade 2–3 vs. grade 1,
&KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF mutant and EREG downregulated,
‘KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF mutant and EREG overexpressed,
£KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF WT EREG downregulated.
doi:10.1371/journal.pone.0015980.t003
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Finally, tumor differentiation (undifferentiated tumors) was signif-
icantly correlated with decreased median OS (Hazard Ratio: 1,9;
p=0.003).
In the multivariate analysis, KRAS (HR 4.3, p,0.0001), BRAF
(HR 5.1, p,0.0001) mutation and low EREG mRNA expression
(HR 1.6, p=0.021) emerged as independent factors associated
with reduced TTP. Furthermore, the absence of severe and
moderate (grade 2–3) skin rash emerged as well, as an independent
prognostic factor for decreased TTP (HR 4.0, p,0.0001)
(Table 5). In addition, KRAS (HR 2.9, p=0.01), BRAF (HR
3.0, p=0.001) mutation and low EREG mRNA expression (HR
1.7, p=0.021) emerged as independent factors associated with
reduced OS. In addition, tumor differentiation grade 3 emerged,
as well, as an independent prognostic factors for reduced OS (HR
2.2, p=0.001). Furthermore, the absence of severe and moderate
(grade 2–3) skin rash emerged as an independent prognostic factor
for decreased OS (HR 3.7, p,0.0001, respectively) (Table 5).
Discussion
Following the discovery of KRAS mutations in association with
anti-EGFR moAbs resistance, the KRAS mutational characteriza-
tion of mCRC tumours is, currently, preformed in routine basis
before any treatment decision. Although the presence of KRAS
mutations is a specific predictive biomarker for lack of anti-EGFR
moAbs efficacy [6–9,14,37] there is convincing evidence that
additional genetic events are involved in this process, since
approximately half of the KRAS wt patients are resistant to such a
treatment [38]. In addition, several biomarkers have been proposed
in association with KRAS mutations as predictive markers for the
efficacy of the anti-EGFR moAbs including BRAF [19,22] or
PIK3CA mutations [21], EGFR ligands overexpression [23,27],
PTENproteinexpression[28] andEGFR copynumbers[10,11].In
the current study we evaluated the predictive significance of other
common mutations observed in CRC in conjunction with PTEN
protein expression and EGFR ligands (EREG and AREG) mRNA
expression as well as the impact of skin rash in a cohort of patients
with mCRC treated with anti-EGFR plus chemotherapy as salvage
treatment. To the best of our knowledge this is the first study which
combines all these parameterstogether. Patient’s characteristics, the
incidence of mutations and the treatment regimens were all typical
for mCRC [22,37]; therefore, the results of our analysis could serve
as a useful guide for clinical practice.
The data presented here are consistent with previous reports
demonstrating that KRAS and BRAF mutations are mutually
exclusive; the prevalence of BRAF mutations (7.2%) is, practically,
similar with that reported in other patients’ series from a first-line
setting [39], but higher than that described in heavily pre-treated
colorectal cancer patients [21,37], indicating that its prognostic
significance mainly depends on the studied patients’ population.
The presence of BRAF mutations has been correlated with
resistance to anti-EGFR moAbs treatment [19,22,34]. In accor-
dance with these previous reports, in the current study we also
observed that patients with tumours that harboured BRAF
mutations had a significantly worse TTP and shorter OS
compared to BRAF wt tumours. Furthermore, in our series of
tumours, a statistically significant correlation was observed
between BRAF mutations and the undifferentiated histological
grade reflecting that this mutation seems to characterize a
subgroup of patients with poor prognosis since they carry a
significant higher risk of progression and death due to disease.
Table 4. TTP and OS to the $2
nd line cetuximab-containing treatment according to KRAS, BRAF, PIK3CA mutations status, PTEN
protein expression, AREG and EREG mRNA expression and grade of skin rash in the KRAS WT patients9 population.
Time to Tumor Progression (months) Overall survival (months)
KRAS WT patients n=75 6.4 months (95% CI 5.4–7.4) 16.3 months (95% CI 12.7–19.6).
Feature
Patients9 population
(No of patients)
Median (months)
(95% CI*)
HR
#
(95% CI) p value
Median (months)
(95% CI)
HR
(95% CI) p value
BRAF status n=75 Mutant (n=8) 2.1 (0.2–3.4) 9.5 (3.9–23.3) ,0.0001 4.3 (0.2–10.3) 4.6 (2.1–10.0) ,0.0001
WT
‘ (n=67) 6.4 (5.3–7.5) 16.3 (13.6–19.1)
PIK3CA status n=75 Mutant (n=8) 4.3(2.3–6.2) 3.3 (1.4–7.7) 0.01 13.5 (4.9–18.8) 1.5 (0.8–3.3) 0.345
WT
‘ (n=67) 6.4 (5.3–7.4) 16.3 (4.9–18.8)
PTEN expression n=74 Loss (n=14) 3.7 (2.9–4.5) 2.7 (1.4–5.1) 0.002 15.3 (6.2–22.8) 1.1 (0.7–2.0) 0.862
Preserved (n=60) 5.0 (4.0–6.0) 14.5 (11.8–21.3)
PIK3CA-PTEN axis n=74 Activated (n=17) 3.8 (2.4–5.2) 2.9 (1.6–5.3) 0.001 13.9 (11.0–18.9) 1.1 (0.7–1.8) 0.987
Normal (n=57) 6.4 (5.7–7.0) 16.2 (13.3–19.1)
AREG expression n=75 Downregulated (n=39) 4.3 (2.8–5.7) 2.0 (1.3–2.5) 0.021 10.7 (11.9–18.2) 2.2 (1.3–3.8) 0.004
Overexpressed (n=36) 5.8 (4.0–7.6) 23.2 (18.5–27.9)
EREG expression n=75 Downregulated (n=39) 3.8 (1.6–5.9) 2.3 (1.4–3.9) 0.001 10.5 (9.4–11.6) 2.9 (1.7–5.0) ,0.0001
Overexpressed (n=36) 7.0 (4.8–9.2) 20.2 (13.4–27.0)
*CI: Confidence Interval,
#HR: Hazard Ration,
‘WT: Wild Type,
$Skin rash grade 2–3 vs. none,
@Skin rash grade 2–3 vs. grade 1,
&KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF mutant and EREG downregulated,
‘KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF mutant and EREG overexpressed,
£KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF WT EREG downregulated.
doi:10.1371/journal.pone.0015980.t004
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been suggested as biomarkers of anti-EGFR moAbs resistance. The
role of PIK3CA mutational status on the anti-EGFR mutational
status is conflicting. In the current study, PIK3CA mutations were
identified in 11 tumours (9.8%) and, more especially, in exon 9 than
in exon 20; this observation is in contrast with that observed in the
Sartore-Bianchi’s et al [21] cohort but in agreement with that
reported by Prenen et al [26]. A significant negative correlation
between PIK3CA mutations and response to anti-EGFR moAbs has
been documented in the Sartore-Bianchi’s et al [21] and the
Perone’s et al [30] reports, whereas, Prenen et al [26] could not find
a clear association between the presence of PIK3CA mutation status
and an impaired efficacy of anti-EGFR moAbs. Our data
demonstrate that there was no significant correlation between the
TTP and OS and the PIK3CA mutational status when the analysis
was performed in the whole group of patients; however, when only
KRAS wt patients were analyzed, PIK3CA mutational status was
correlated with a significantly lower TTP. Nevertheless, this lower
TTP could not be translated into differences in OS between wt
KRAS patients with mutant and wt PIK3CA alleles in their primary
tumours, as previously described by our group [22]. In a very recent
study by De Roock et al [40], where a large cohort of patients has
been evaluated, the role of PIK3CA mutational status has been more
clearly revealed. Exon 9 and exon 20 PIK3CA mutations were able
to be analyzed separately and, indeed, only exon 20 mutations were
found to be associated with a worse outcome after cetuximab
administration. This seems to be a possible explanation for the
reported conflicting results published in the literature, since there
could be more than one interpretation when two events (exon 9 and
exon 20 mutations) have different and opposite effects. However,
the lack of efficacy of EGFR moAbs which is observed in patients
with mutant KRAS extends to other common mutations that
deregulate the cellular signaling pathway, especially BRAF and,
probably, PIK3CA [41].
The role of PTEN loss and consecutive over-activation of the
AKT pathway and its evaluation is still under investigation, as far
as response to anti-EGFR moAbs is concerned. Five relatively
small, retrospective studies [26,28–30] have provided evidence
that PTEN status is associated with objective responses in
cetuximab-treated mCRC patients suggesting that PTEN-positive
tumours tend to have a better outcome than negative ones;
however, another study failed to confirm this observation [21].
This probably could be due to several methodological differences
such as the used anti-PTEN antibodies, the IHC scoring
algorithms and cut-off criteria [31,42]. In the present study, the
significantly lower TTP which was observed in patients with wt
KRAS and PIK3CA according to the down- and up-regulation of
PTEN could not be translated into differences in OS. Neverthe-
less, since PTEN IHC is not yet adequately validated, it cannot be
considered for immediate routine clinical use, but, it should be
kept in mind in the planning process of prospective biomarkers
studies.
EGFR ligands AREG and EREG were quite recently found by
biomarker exploratory analysis using Affimetrix to be the top
genes associated with efficacy to anti-EGFR moAbs [27]. In the
group of patients with wt KRAS we found a statistically significant
correlation of AREG and especially EREG mRNA overexpression
with increased TTP and OS in accordance with previous reports
[23]. Our data also seem to identify a subgroup of KRAS wt
patients who could be considered to more EGFR-dependent and,
thus, have a higher probability of responding to EGFR inhibition
as already previously has been reported [23]. Patients whose
tumours were characterized by ligands’ downregulation behaved
like KRAS mutants upon treatment with anti-EGFR moAbs.
The most frequently reported side effect of EGFR inhibitors is a
dose-dependent acneiform skin rash occurring in more than 50%
of patients [42]. A number of studies have suggested that from a
clinical point of view, the severity of skin rash is positively
correlated with clinical outcome (response rates, progression free
survival and OS) and, thus, it could be used in order to distinguish
mCRC patients more likely to be sensitive to anti-EGFR
treatment [2,32,42]. Particularly, the analysis of the PRIME trial
showed that the patients with KRAS mutated tumours and
moderate or severe skin rash presented better outcome in
comparison with those with KRAS wt tumours and no or mild
skin rash [32]. In our study as well, mCRC patients with severe
and moderate skin rash presented significantly higher TTP and
OS compared with those with mild and no rash. Indeed, in the
multivariate analysis the absence of severe and moderate (grade 3
and 2) skin rash formation emerged as an independent predictive
factor for reduced TTP and OS. Although skin toxicity seems to
be an important clinical surrogate marker of anti-EGFR moAbs
Figure 2. Patients’ outcome according to KRAS mutations
status. Panel A: Time to Tumor Progression (TTP) Panel B: Median
Overall Survival (OS).
doi:10.1371/journal.pone.0015980.g002
Biomarkers to Anti-EGFR moABS in mCRC
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e15980Figure 3. Patients’ outcome according to BRAF mutations status. Panel A: Time to Tumor Progression (TTP) in the whole patients’ population.
Panel B: Median Overall Survival (OS) in the whole patients’ population Panel C: Time to Tumor Progression (TTP) in patients with KRAS wt primary
tumors. Panel D: Median Overall Survival (OS) in patients with KRAS wt primary tumors.
doi:10.1371/journal.pone.0015980.g003
Figure 4. Time to Tumor Progression (TTP according to PIK3CA mutations status and PTEN expression. Panel A: according to PIK3CA
mutations status in the whole patients’ population. Panel B: according to PTEN expression in the whole patients’ population. Panel C: according to
PIK3-PTEN axis activation status (PIK3CA mutations status and PTEN expression) in the whole patients’ population. Panel D: according to PIK3CA
mutations status in patients with KRAS wt primary tumors. Panel E: according to PTEN expression in patients with KRAS wt primary tumors. Panel F:
according to PIK3-PTEN axis activation status (PIK3CA mutations status and PTEN expression) in patients with KRAS wt primary tumors.
doi:10.1371/journal.pone.0015980.g004
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e15980Figure 5. Median Overall Survival (OS) according to PIK3CA mutations status and PTEN expression. Panel A: according to PIK3CA
mutations status in the whole patients’ population. Panel B: according to PTEN expression in the whole patients’ population. Panel C: according to
PIK3-PTEN axis activation status (PIK3CA mutations status and PTEN expression) in the whole patients’ population. Panel D: according to PIK3CA
mutations status in patients with KRAS wt primary tumors. Panel E: according to PTEN expression in patients with KRAS wt primary tumors. Panel F:
according to PIK3-PTEN axis activation status (PIK3CA mutations status and PTEN expression) in patients with KRAS wt primary tumors.
doi:10.1371/journal.pone.0015980.g005
Figure 6. Patients’ outcome according to AREG mRNA expression. Panel A: Time to Tumor Progression (TTP) in the whole patients’
population. Panel B: Median Overall Survival (OS) in the whole patients’ population Panel C: Time to Tumor Progression (TTP) in patients with KRAS wt
primary tumors. Panel D: Median Overall Survival (OS) in patients with KRAS wt primary tumors.
doi:10.1371/journal.pone.0015980.g006
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e15980Figure 7. Patients’ outcome according to EREG mRNA expression. Panel A: Time to Tumor Progression (TTP) in the whole patients’
population. Panel B: Median Overall Survival (OS) in the whole patients’ population Panel C: Time to Tumor Progression (TTP) in patients with KRAS wt
primary tumors. Panel D: Median Overall Survival (OS) in patients with KRAS wt primary tumors.
doi:10.1371/journal.pone.0015980.g007
Figure 8. Patients’ outcome according to KRAS-BRAF mutations status and AREG or EREG mRNA expression. Panel A: Time to Tumor
Progression (TTP) according to KRAS-BRAF mutations status and AREG mRNA expression. Panel B: Median Overall Survival (OS) according to KRAS-BRAF
mutations status and AREG mRNA expression. Panel C: Time to Tumor Progression (TTP) according to KRAS-BRAF mutations status and EREG mRNA.
Panel D Median Overall Survival (OS) according to KRAS-BRAF mutations status and EREG mRNA.
doi:10.1371/journal.pone.0015980.g008
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elucidation of the biologic mechanisms will be of great value.
The multivariate analysis revealed that the presence of KRAS or
BRAF mutations and EREG downregulation are the only
biomarkers which are independent prognostic factors for
decreased TTP and OS. In a recently published study, the
mutational analysis of KRAS, BRAF, NRAS and PIK3CA exon 20, in
that specific order, has been proposed as the most effective
approach [40]. The common finding between the two studies is
that multigene models seem to be more effective than single-gene
analysis for the selection of patients who could gain the maximum
benefit from the administration of anti-EGFR moAbs. The
important issue of cost for the molecular analysis and the limited
amount of tumour cells available in FFPE specimens for all
potential biomarkers testing could be tackled with the develop-
ment of multiplex assays [43]. Furthermore, the severity of skin
rash during the treatment with anti-EGFR mo-Abs has been
constantly reported as a predictive factor for response and survival
[2,16], and this was also the case in the present study, since the
severity of skin rash was an independent predictive factor for TTP
Figure 9. Patients’ outcome according to severity of skin rash during the cetuximab administration. Panel A: Time to Tumor Progression
(TTP) according to the worst skin rash grade developed during the treatment with cetuximab + chemotherapy. Panel B: Median Overall Survival (OS)
according to the worst skin rash grade developed during the treatment with cetuximab + chemotherapy.
doi:10.1371/journal.pone.0015980.g009
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severe skin rash and tumor response is not yet elucidated, and very
few data are published regarding this issue [44].
In summary, the genetics underpinnings of CRC are established
[45] and the results of the present study support the idea that
advanced application of CRC genetic profiling could lead to
informed treatment decisions. Despite the fact that the results of a
retrospective study should be interpreted with caution, it seems
that the determination of the KRAS-BRAF mutational status, with
additional screening of CRC tumours for their EREG mRNA
expression, could help stratify patients likely to benefit from a
regimen containing an anti-EGFR moAb. Studies which focus in
the elucidation of the mechanism which links the development of
skin rash with tumors response are urgently warranted. Never-
theless, since most available data come from retrospective studies,
validation in prospective randomized clinical trials is imperative in
order to formally confirm the predictive and prognostic value of
these biomarkers.
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